JP3748941B2 - Anti-aging cosmetic - Google Patents
Anti-aging cosmetic Download PDFInfo
- Publication number
- JP3748941B2 JP3748941B2 JP11082296A JP11082296A JP3748941B2 JP 3748941 B2 JP3748941 B2 JP 3748941B2 JP 11082296 A JP11082296 A JP 11082296A JP 11082296 A JP11082296 A JP 11082296A JP 3748941 B2 JP3748941 B2 JP 3748941B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- cells
- hibiscus
- medium
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Description
【0001】
【産業上の利用分野】
本発明は、皮膚線維芽細胞の増殖を活性化し、細胞外マトリックス産生を増加させることにより、皮膚のはり・しわを改善する皮膚老化防止効果に優れた老化防止化粧料に関する。
【0002】
【従来の技術および課題】
近年、健康で美しい肌を保つことが、老若男女を問わず、重大な関心事になっている。ところが、肌は、加齢などの内的因子や紫外線、活性酸素などの外的因子によって、皮膚が本来維持している収縮性、柔軟性、保湿性などの機能が衰え、様々なトラブルを発生する。
これらのトラブルのひとつであるしわは、真皮の細胞外マトリックスを産生する細胞数の減少、分裂速度の衰えなどの細胞機能の老化や、コラーゲン線維の減少および変性、皮下脂肪組織の減少などにより、皮膚の弛緩および弾力性の損失が起こることが原因となって発生する。
従来、皮膚老化への対処法としては、老化によって失われるコラーゲン、ヒアルロン酸などの物質を皮膚に塗布し補う組成物や、紫外線や活性酸素から皮膚を守るための防御物質を配合した間接的な老化防止剤が主流であった。
【0003】
【発明者が解決しようとする課題】
しかしながらこれらの方法は満足のいく効果を奏するものではなかった。また、老化を根本的に改善しようとする試みとしてはレチノイン酸などがあるが、安全性に問題があり、長期使用に耐え得るものではなかった。
従って、皮膚の老化を改善し、しかも皮膚に弊害がなく、安全に使用できる老化防止化粧料の開発が望まれている。
【0004】
【問題を解決する手段】
そこで本発明者らは、かかる実情に鑑み鋭意検討した結果、ハイビスカス自体又はその有機溶媒及び/又は水による抽出物が、皮膚線維芽細胞の細胞増殖を活性化し、細胞外マトリックスの産生を増加させることにより、皮膚のはり・しわの改善に顕著な作用を示すことを見出し、本発明を完成するに至った。
【0005】
すなわち、本発明は、ハイビスカス自体又はその有機溶媒及び/又は水による抽出物を含有することを特徴とする老化防止化粧料を提供するものである。
【0006】
本発明で使用されるハイビスカス(学名:Hibiscus sabdariffa L.)は通常、各種溶剤で抽出し、抽出物(エキス)として使用するが、抽出液をそのまま使用してもよいし、乾燥粉体として使用してもよい。また、ハイビスカスをそのまま小片に裁断して小片状で使用しても、或いは乾燥後、粉砕して粉末状で使用してもよい。
【0007】
ここで前記抽出物を得る方法としては公知の方法が利用できる。
植物抽出物は上記ハイビスカス、好ましくは乾燥末化したものを水もしくは有機溶媒(ヘキサン、エーテル、酢酸エチル、ブタノール、アセトン、プロパノール、エタノール、メタノール、プロピレングリコール、1,3ブチレングリコール)あるいはそれらを一定の比率で混合した溶媒、たとえば水性アルコールを用い、通常4℃〜100℃で抽出して得られる。こうして得られた抽出物は、必要に応じて活性炭又は活性白土等により精製する。
一般的には配合量は目的に応じ、0.001〜100重量%を任意に配合、使用する。
【0008】
【実施例】
以下、実施例により本発明を詳細に説明するが、本発明はこれらに限定されるものではない。
【0009】
(ハイビスカス抽出物 製造例) 原材料として、ハイビスカスの乾燥物を300g使用した。前記原材料300gにイオン交換水450mlを加え、60℃で3時間加熱抽出した後No.2濾紙にて濾過する。全ての濾液を合わせ、HP-20(三菱化成社製:φ=50mm,h=500mm)カラムクロマトグラフィーに付し、HP-20未吸着画分を、ロータリーエバポレーターにて減圧濃縮、凍結乾燥し、ハイビスカス抽出物120gを得た(収量40%)。
【0010】
<実験例1>皮膚線維芽細胞増殖試験
(1)試験溶液調製
前記ハイビスカス抽出物をCa2+,Mg2+不含有PBS(phosphate buffered saline。蒸留水1lあたり、NaCl 8.0g, KCl 0.2g, KH2PO4 0.2g, Na2HPO4・12H20 2.9g )に0.1(w/v)%になるように溶解後、0.2μmメンブランフィルターにて濾過滅菌し、適宜希釈したものを、試験溶液とした。
(2)細胞培養
正常ヒト2倍体線維芽細胞HFSKF-II(理化学研究所製)を、Ham-F12(大日本製薬社製)に15(v/v)%の牛胎児血清を添加したもので培養した。前記培地にて1×105cell/mlに調整した細胞を、内径16mmの滅菌プラスチック24穴プレートに0.5mlずつ接種し、24時間培養後、試験溶液を10(v/v)%含む培地に交換し、その後48時間培養した。
(3)細胞数測定
前記のように培養後、24穴プレートの培地を捨て、Ca2+,Mg2+不含有PBSで細胞を洗浄後、トリプシンを用いて細胞を剥離し、細胞数を測定し、細胞増殖作用を検討した。これらの結果を第1表に示す。なお、ネガティブコントロールとしてはCa2+,Mg2+不含有PBSを用いた。
【0011】
【表1】
皮膚線維芽細胞増殖試験結果
【0012】
表1の結果より、前記ハイビスカス抽出物は皮膚線維芽細胞の増殖効果を有することが見いだされた。
【0013】
<実験例2>皮膚線維芽細胞賦活試験
MTT(3-(4,5-ジメチルチアゾール-2-イル)-2,5-ジフェニルーテトラゾリウムブロマイド)は生細胞中に取り込まれるとミトコンドリア中の酵素の作用を間接的に受けてTetrazolium環が還元的に開裂し、青色のFormazanを形成する。細胞中で生成されるFormazan量は細胞のミトコンドリアのエネルギー代謝(呼吸酵素活性)と良好な相関があるため、MTT還元法によって細胞賦活効果を評価できる。
(1)試験溶液調製
前記ハイビスカス抽出物をCa2+,Mg2+不含有PBSで希釈し、0.2μmメンブランフィルターにて濾過滅菌したものを、試験溶液とした。
(2)MTTストック溶液の調製
MTT(3-(4,5-ジメチルチアゾール-2-イル)-2,5-ジフェニルーテトラゾリウムブロマイド)5mgをCa2+,Mg2+不含有PBS 1mlに溶解した溶液をフィルターで濾過後、滅菌してMTTストック溶液を調製した。
(3)細胞培養
正常ヒト2倍体線維芽細胞HFSKF-IIを、Ham-F12(大日本製薬社製)に15(v/v)%の牛胎児血清を添加したもので培養した。前記培地にて1×105cell/mlに調整した細胞を、内径16mmの滅菌プラスチック24穴プレートに0.5mlずつ接種し、24時間培養後、試験溶液を10(v/v)%含む培地に交換し、その後48時間培養した。24穴プレートの培地を捨て、Ca2+,Mg2+不含有PBSで細胞を洗浄後、前記MTTストック溶液を10mlMTTストック/100μl培地となるように加え、4時間培養した。培地を除去し、酸性イソプロパノール(特級塩酸を0.04Nになるようイソプロパノールに添加した溶液)を各ウェルに600μl添加、攪拌後、波長570nmで吸光度を測定し、波長650nmで測定した濁度の吸光度を差し引いてFormazanの生成量として評価した。これらの結果を表2に示す。なお、ネガティブコントロールとしてはCa2+,Mg2+不含有PBSを用いた。
【0014】
【表2】
皮膚線維芽細胞賦活試験結果
【0015】
表2の結果より、前記ハイビスカス抽出物は線維芽細胞賦活効果を有することが見いだされた。
【0016】
<実験例3>皮膚線維芽細胞コラーゲン合成促進試験
(1)試験溶液調製
前記ハイビスカス抽出物をCa2+,Mg2+不含有PBSで希釈し、0.2μmメンブランフィルターにて濾過滅菌したものを、試験溶液とした。
(2)細胞培養
正常ヒト2倍体線維芽細胞HFSKF-IIを、Ham-F12(大日本製薬社製)に15(v/v)%の牛胎児血清を添加したもので培養した。前記培地にて1×105cell/mlに調整した細胞を、内径32mmの滅菌プラスチック12穴プレートに1.0mlずつ接種し、120時間培養後、試験溶液を10(v/v)%含む無血清線維芽細胞増殖培地F-GM(クラボウ社製)に交換し、その後48時間培養を行った。
(3)細胞数の測定
前記のように培養後、12穴シャーレの培地を捨て、Ca2+,Mg2+不含有PBSで細胞を洗浄し、トリプシンを用いて細胞を剥離し、細胞数を測定した。試験溶液のネガティブコントロールとしてはCa2+,Mg2+不含有PBSを使用した。
(4)培地内コラーゲン量の測定
培地内コラーゲン量は、前記(2)のように培養後、12穴プレートの各ウェルの培地を採取し、Ca2+,Mg2+不含有PBSにより細胞を洗浄した液を加えた溶液中に存在するヒドロキシプロリンの含量を定量することにより測定した。ヒドロキシプロリンはコラーゲンに特徴的なアミノ酸である。ヒドロキシプロリン量は、Inayama,Shibata,Ohtuki,Saitoの方法(藤本大三郎、永井裕(1985)、コラーゲン実験法、pp.51-56、講談社)に準じ、以下の方法により測定した。まず、培地に等容の12N-HClを加え、110℃、24時間加熱する。加水分解後、HClはロータリーエバポレーターで除去しておく。蒸留水2ml、KCl 1.5g、ホウ酸緩衝液(蒸留水1l当たり、ホウ酸 61.84g、KCl 225g、pH8.7)0.5mlを加え、室温で20分間静置する。クロラミンT溶液(p-トルエンスルホンクロロアミドナトリウム三水和物 1.41gを2ーメトキシエタノール25mlに溶解)0.5mlを加えて25分間適宜振とうし、さらに3.6Mチオ硫酸ナトリウム溶液 1.5mlを加え、密栓し、100℃で30分間加熱する。冷却した後、トルエンを2.5ml加え5分間振とう後、トルエン層を採取し、無水硫酸ナトリウムのカラム(6mm2×30mm)を通過させる。流出液1.0mlをとり、p-ジメチルアミノベンズアルデヒド溶液 0.5ml(p-ジメチルアミノベンズアルデヒド 120gをエタノール 200mlに溶解した液と、濃硫酸 27.4mlをエタノール 200mlに溶解した液を、氷冷下で混合)と混合し、室温で30分間放置後、560nmの吸光度を測定する。 コラーゲン量を前記(3)で測定した細胞数で割り、細胞数あたりの培地内コラーゲン量を算出する。試験溶液のネガティブコントロールとしてはCa2+,Mg2+不含有PBSを使用した。コラーゲン合成促進率は次式を用い、ネガティブコントロールのコラーゲン量を100%として計算を行った。
【0017】
【数1】
培地内コラーゲン合成率(%)=(Sx/Cx)× 100
Sx;試料溶液を添加したウェルにおける細胞数あたりの培地内コラーゲン量
Cx;Ca2+,Mg2+不含有PBSを添加したウェルにおける 細胞数あたりの培地内コラーゲン量
これらの結果を表3に示す。なお、ネガティブコントロールとしてはCa2+,Mg2+不含有PBSを用いた。
【0018】
【表3】
皮膚線維芽細胞コラーゲン合成促進試験結果
【0019】
表3の結果より、前記ハイビスカス抽出物は皮膚線維芽細胞のコラーゲン合成促進効果を有することが見いだされた。
【実験例4】マウス皮膚塗布試験
実験動物としてICR系雌マウス(リタイア)を用い、バリカンにて剃毛した背部皮膚にハイビスカスエキスを10(v/v)%エタノールに溶解した溶液を1日1回0.2ml、5日/週、塗布した。4週間後、マウス背部から直径12mmの皮膚を採取した。採取した皮膚はを重量を測定後、アセトンにて脱水・脱脂後均質化し、実験例3(4)に示したInayama,Shibata,Ohtuki,Saitoの方法(藤本大三郎、永井裕(1985)、コラーゲン実験法、pp.51-56、講談社)に準じてコラーゲン量を算出した。これらの結果を表4に示す。なお、ネガティブコントロールとしては10(v/v)%エタノール溶液を用いた。
【0020】
【表4】
マウス皮膚塗布試験結果
【0021】
表4の結果より、前記ハイビスカス抽出物はマウス皮膚のコラーゲン量を増加させる効果を有することが見いだされた。
【0022】
【処方例】以下に本発明の処方例を挙げる。
【0023】
【0024】
【0025】
【0026】
【0027】
【0028】
【発明の効果】
本発明によれば、ハイビスカス自体又はその有機溶媒及び/又は水による抽出物を含有した安全な老化防止化粧料が提供され、該老化防止化粧料は皮膚全体の老化を根本的に改善することができるため、いつまでもみずみずしくはりのある肌を保つことができる。[0001]
[Industrial application fields]
The present invention relates to an anti-aging cosmetic excellent in skin aging prevention effect that improves skin creases and wrinkles by activating proliferation of dermal fibroblasts and increasing extracellular matrix production.
[0002]
[Prior art and problems]
In recent years, maintaining healthy and beautiful skin has become a major concern for both young and old. However, due to internal factors such as aging and external factors such as ultraviolet rays and active oxygen, the skin's inherent functions such as contractility, flexibility, and moisture retention are reduced, causing various problems. To do.
Wrinkles, one of these troubles, are due to aging of cellular functions such as a decrease in the number of cells that produce the extracellular matrix of the dermis, a decrease in division rate, a decrease and degeneration of collagen fibers, a decrease in subcutaneous adipose tissue, etc. Occurs due to skin relaxation and loss of elasticity.
Conventionally, skin aging has been dealt with by a composition that supplements the skin with substances such as collagen and hyaluronic acid that are lost due to aging, and an indirect combination of protective substances that protect the skin from ultraviolet rays and active oxygen. Anti-aging agents were mainstream.
[0003]
[Problems to be solved by the inventor]
However, these methods have not been satisfactory. In addition, retinoic acid is an attempt to fundamentally improve aging, but it has a safety problem and cannot withstand long-term use.
Therefore, it is desired to develop an anti-aging cosmetic that can improve skin aging and that can be safely used without causing any harmful effects on the skin.
[0004]
[Means to solve the problem]
Thus, as a result of intensive studies in view of such circumstances, the present inventors have found that hibiscus itself or an extract thereof with organic solvent and / or water activates cell proliferation of dermal fibroblasts and increases production of extracellular matrix. As a result, it has been found that it has a remarkable effect on the improvement of skin creases and wrinkles, and has led to the completion of the present invention.
[0005]
That is, this invention provides the anti-aging cosmetics characterized by including the extract by hibiscus itself or its organic solvent, and / or water.
[0006]
Hibiscus (scientific name: Hibiscus sabdariffa L.) used in the present invention is usually extracted with various solvents and used as an extract, but the extract may be used as it is or as a dry powder. May be. Further, the hibiscus may be cut into small pieces as they are and used in the form of small pieces, or may be used after being dried and pulverized into powder.
[0007]
Here, a known method can be used as a method for obtaining the extract.
The plant extract is the above hibiscus, preferably dried powder, water or an organic solvent (hexane, ether, ethyl acetate, butanol, acetone, propanol, ethanol, methanol, propylene glycol, 1,3 butylene glycol) or a constant thereof. It is usually obtained by extraction at 4 to 100 ° C. using a solvent mixed at a ratio of The extract thus obtained is purified with activated carbon or activated clay as required.
Generally, the blending amount is arbitrarily blended and used in an amount of 0.001 to 100% by weight depending on the purpose.
[0008]
【Example】
EXAMPLES Hereinafter, although an Example demonstrates this invention in detail, this invention is not limited to these.
[0009]
(Hibiscus extract production example) As a raw material, 300 g of dried hibiscus was used. Add 450 ml of ion-exchanged water to 300 g of the raw material, heat extract at 60 ° C. for 3 hours, and filter through No. 2 filter paper. All the filtrates were combined, subjected to HP-20 (Mitsubishi Kasei Co., Ltd .: φ = 50 mm, h = 500 mm) column chromatography, HP-20 non-adsorbed fraction was concentrated under reduced pressure on a rotary evaporator, and lyophilized. 120 g of hibiscus extract was obtained (yield 40%).
[0010]
<Experimental Example 1> Skin Fibroblast Proliferation Test (1) Preparation of Test Solution The hibiscus extract was mixed with PBS containing no Ca 2+ and Mg 2+ (phosphate buffered saline. NaCl 8.0 g, KCl 0.2 g per liter of distilled water, KH 2 PO 4 0.2 g, Na 2 HPO 4 · 12H 2 2.9 g) 0.1% (w / v)% dissolved, then sterilized by filtration through a 0.2 μm membrane filter, and diluted as appropriate. It was set as the solution.
(2) Cell culture normal human diploid fibroblast HFSKF-II (manufactured by RIKEN), Ham-F12 (manufactured by Dainippon Pharmaceutical Co., Ltd.) with 15 (v / v)% fetal bovine serum In culture. Cells adjusted to 1 × 10 5 cell / ml in the above medium are inoculated in 0.5 ml sterilized plastic 24-well plates with an inner diameter of 16 mm, cultured for 24 hours, and then added to a medium containing 10 (v / v)% test solution. After changing, the cells were cultured for 48 hours.
(3) Cell number measurement After culturing as described above, discard the medium from the 24-well plate, wash the cells with PBS without Ca 2+ and Mg 2+ , detach the cells using trypsin, and measure the number of cells. Then, the cell proliferation effect was examined. These results are shown in Table 1. As a negative control, PBS containing no Ca 2+ and Mg 2+ was used.
[0011]
[Table 1]
Skin fibroblast proliferation test results
[0012]
From the results in Table 1, it was found that the hibiscus extract had a skin fibroblast proliferation effect.
[0013]
<Experimental example 2> Skin fibroblast activation test
When MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl-tetrazolium bromide) is taken into living cells, it is indirectly affected by enzymes in mitochondria and the Tetrazolium ring is reduced. Cleaves to form a blue Formazan. Since the amount of Formazan produced in the cell has a good correlation with mitochondrial energy metabolism (respiratory enzyme activity) in the cell, the cell activation effect can be evaluated by the MTT reduction method.
(1) Preparation of test solution The hibiscus extract was diluted with PBS containing no Ca 2+ and Mg 2+ and sterilized by filtration through a 0.2 μm membrane filter to obtain a test solution.
(2) Preparation of MTT stock solution
A solution of 5 mg of MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl-tetrazolium bromide) dissolved in 1 ml of Ca 2+ and Mg 2 + -free PBS is filtered through a filter and sterilized. An MTT stock solution was prepared.
(3) Cell culture Normal human diploid fibroblast HFSKF-II was cultured in Ham-F12 (Dainippon Pharmaceutical Co., Ltd.) supplemented with 15 (v / v)% fetal bovine serum. Cells adjusted to 1 × 10 5 cell / ml in the above medium are inoculated in 0.5 ml sterilized plastic 24-well plates with an inner diameter of 16 mm, cultured for 24 hours, and then added to a medium containing 10 (v / v)% test solution. After changing, the cells were cultured for 48 hours. After discarding the medium from the 24-well plate and washing the cells with Ca 2+ , Mg 2+ -free PBS, the MTT stock solution was added to a 10 ml MTT stock / 100 μl medium and cultured for 4 hours. Remove the medium, add 600 μl of acidic isopropanol (a solution in which special grade hydrochloric acid is added to isopropanol to 0.04 N) to each well, stir, measure the absorbance at a wavelength of 570 nm, and measure the absorbance of the turbidity measured at a wavelength of 650 nm. Subtracted and evaluated as the amount of Formazan produced. These results are shown in Table 2. As a negative control, PBS containing no Ca 2+ and Mg 2+ was used.
[0014]
[Table 2]
Skin fibroblast activation test results
[0015]
From the results in Table 2, it was found that the hibiscus extract had a fibroblast activation effect.
[0016]
<Experimental Example 3> Skin Fibroblast Collagen Synthesis Promotion Test (1) Preparation of test solution The hibiscus extract was diluted with PBS not containing Ca 2+ and Mg 2+ and sterilized by filtration through a 0.2 μm membrane filter. A test solution was obtained.
(2) Cell culture Normal human diploid fibroblast HFSKF-II was cultured in Ham-F12 (Dainippon Pharmaceutical Co., Ltd.) supplemented with 15 (v / v)% fetal bovine serum. Cells adjusted to 1 × 10 5 cells / ml in the above medium are inoculated 1.0 ml each into a sterilized plastic 12-well plate with an inner diameter of 32 mm, cultured for 120 hours, and then serum-free containing 10 (v / v)% test solution The fibroblast growth medium F-GM (manufactured by Kurabo Industries Co., Ltd.) was replaced, and then cultured for 48 hours.
(3) Measurement of the number of cells After culturing as described above, discard the 12-well Petri dish medium, wash the cells with PBS containing no Ca 2+ or Mg 2+ , detach the cells using trypsin, and determine the number of cells. It was measured. As a negative control of the test solution, Ca 2+ and Mg 2+ -free PBS was used.
(4) Measurement of the amount of collagen in the medium The amount of collagen in the medium was determined by collecting the medium in each well of the 12-well plate after culturing as in (2) above, and then culturing the cells with PBS containing no Ca 2+ or Mg 2+. It was measured by quantifying the content of hydroxyproline present in the solution to which the washed liquid was added. Hydroxyproline is an amino acid characteristic of collagen. The amount of hydroxyproline was measured by the following method according to the method of Inayama, Shibata, Ohtuki, Saito (Daizaburo Fujimoto, Hiroshi Nagai (1985), collagen experiment method, pp. 51-56, Kodansha). First, an equal volume of 12N-HCl is added to the medium and heated at 110 ° C. for 24 hours. After hydrolysis, HCl is removed with a rotary evaporator. Add 2 ml of distilled water, 1.5 g of KCl, and borate buffer (0.5 ml of boric acid 61.84 g, KCl 225 g, pH 8.7 per liter of distilled water) and let stand at room temperature for 20 minutes. Add 0.5 ml of chloramine T solution (1.41 g of p-toluenesulfone chloroamide sodium trihydrate dissolved in 25 ml of 2-methoxyethanol), shake for 25 minutes as appropriate, and then add 1.5 ml of 3.6 M sodium thiosulfate solution. Seal and heat at 100 ° C for 30 minutes. After cooling, 2.5 ml of toluene is added and shaken for 5 minutes. The toluene layer is collected and passed through an anhydrous sodium sulfate column (6 mm 2 × 30 mm). Take 1.0 ml of the effluent, 0.5 ml of p-dimethylaminobenzaldehyde solution (mixed in a solution of 120 g of p-dimethylaminobenzaldehyde in 200 ml of ethanol and 27.4 ml of concentrated sulfuric acid in 200 ml of ethanol) After mixing for 30 minutes at room temperature, the absorbance at 560 nm is measured. The amount of collagen is divided by the number of cells measured in (3) above, and the amount of collagen in the medium per number of cells is calculated. As a negative control of the test solution, Ca 2+ and Mg 2+ -free PBS was used. The collagen synthesis acceleration rate was calculated using the following formula, assuming the amount of collagen in the negative control as 100%.
[0017]
[Expression 1]
Collagen synthesis rate in medium (%) = (Sx / Cx) x 100
Sx: amount of collagen in the medium per number of cells in the well to which the sample solution was added
Table 3 shows the amount of collagen in the medium per number of cells in wells to which PBS containing Cx; Ca 2+ and Mg 2+ was not added. As a negative control, PBS containing no Ca 2+ and Mg 2+ was used.
[0018]
[Table 3]
Skin fibroblast collagen synthesis promotion test results
[0019]
From the results of Table 3, it was found that the hibiscus extract had an effect of promoting collagen synthesis in dermal fibroblasts.
[Experimental Example 4] Mouse skin application test An ICR female mouse (retire) was used as an experimental animal. Application was 0.2 ml, 5 days / week. After 4 weeks, skin with a diameter of 12 mm was collected from the back of the mouse. The collected skin was weighed, homogenized after dehydration and degreasing with acetone, and the method of Inayama, Shibata, Ohtuki, Saito shown in Experimental Example 3 (4) (Daizaburo Fujimoto, Hiroshi Nagai (1985), collagen experiment) Method, pp. 51-56, Kodansha). These results are shown in Table 4. As a negative control, a 10 (v / v)% ethanol solution was used.
[0020]
[Table 4]
Mouse skin application test results
[0021]
From the results in Table 4, it was found that the hibiscus extract had an effect of increasing the amount of collagen in mouse skin.
[0022]
[Formulation examples] The following are examples of the present invention.
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
【The invention's effect】
ADVANTAGE OF THE INVENTION According to this invention, the safe anti-aging cosmetics containing the hibiscus itself or its organic solvent and / or the extract by water are provided, and this anti-aging cosmetic can fundamentally improve the aging of the whole skin. Because it can, you can keep the skin with a fresh and continuous skin.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11082296A JP3748941B2 (en) | 1996-05-01 | 1996-05-01 | Anti-aging cosmetic |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11082296A JP3748941B2 (en) | 1996-05-01 | 1996-05-01 | Anti-aging cosmetic |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09295928A JPH09295928A (en) | 1997-11-18 |
JP3748941B2 true JP3748941B2 (en) | 2006-02-22 |
Family
ID=14545546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11082296A Expired - Lifetime JP3748941B2 (en) | 1996-05-01 | 1996-05-01 | Anti-aging cosmetic |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3748941B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009084742A2 (en) | 2009-03-30 | 2009-07-09 | Shiseido Company, Ltd. | Fibroblast proliferator |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1036279A (en) * | 1996-07-18 | 1998-02-10 | Ichimaru Pharcos Co Ltd | Fibroblast proliferation promoting agent containing vegetable extract |
KR100330137B1 (en) * | 1999-07-16 | 2002-03-27 | 복성해 | Novel triterpene-series chemical compound capable of inhibiting lipid-peroxidation and process for preparation thereof |
JP4754671B2 (en) * | 1999-11-30 | 2011-08-24 | 花王株式会社 | Cosmetics |
US6849278B2 (en) * | 2001-11-21 | 2005-02-01 | Universal Biotech Co., Ltd. | Method to counter oxidation of LDL, decrease triglyceride or cholesterol and inhibit atherosclerosis using Hibiscus sabdariffa extract |
JP4081408B2 (en) * | 2003-06-06 | 2008-04-23 | 株式会社ナリス化粧品 | Skin preparation |
JP4902967B2 (en) * | 2005-03-31 | 2012-03-21 | 小林製薬株式会社 | Melanin production inhibitor |
WO2006106992A1 (en) * | 2005-03-31 | 2006-10-12 | Kobayashi Pharmaceutical Co., Ltd. | Melanin production inhibitory agent |
JP5129440B2 (en) * | 2005-06-14 | 2013-01-30 | 共栄化学工業株式会社 | Fermented plant and cosmetics containing the same |
JP4456585B2 (en) * | 2006-09-06 | 2010-04-28 | 株式会社ノエビア | Cell activator, collagen production promoter, whitening agent, antioxidant, anti-inflammatory agent, aromatase activity promoter, protease activity promoter, topical skin preparation and food |
US20130302279A1 (en) * | 2012-04-20 | 2013-11-14 | University Of Medicine & Dentistry Of New Jersey | Identification of natural plant extracts harboring anti-hepatitis c virus ns5b polymerase activity |
JP6485995B2 (en) * | 2013-05-10 | 2019-03-20 | 丸善製薬株式会社 | Endothelin-1 mRNA expression increase inhibitor, stem cell growth factor mRNA expression increase inhibitor, basic fibroblast growth factor mRNA expression increase inhibitor, and proopiomelanocortin mRNA expression increase inhibitor |
JP6928429B2 (en) * | 2016-08-05 | 2021-09-01 | 共栄化学工業株式会社 | Topical skin agent |
JP6969042B2 (en) * | 2018-09-14 | 2021-11-24 | 丸善製薬株式会社 | Claudin-1 production promoter, occludin production promoter, epidermal tight junction constituent protein production promoter in human skin three-dimensional model, and skin barrier function decline inhibitor |
CN109403026A (en) * | 2018-10-31 | 2019-03-01 | 嘉兴珠韵服装有限公司 | A kind of preparation method of dyeing and finishing technology pretreating reagent |
WO2021084665A1 (en) * | 2019-10-30 | 2021-05-06 | 株式会社 資生堂 | Platelet-derived growth factor (pdgf)-bb production promoter, stem cell stabilizer containing this, and skin anti-aging agent containing these |
JP7220488B2 (en) * | 2020-05-25 | 2023-02-10 | 丸善製薬株式会社 | Testosterone 5α-reductase activity inhibitor or glutathione production promoter |
-
1996
- 1996-05-01 JP JP11082296A patent/JP3748941B2/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009084742A2 (en) | 2009-03-30 | 2009-07-09 | Shiseido Company, Ltd. | Fibroblast proliferator |
KR20120041090A (en) | 2009-03-30 | 2012-04-30 | 가부시키가이샤 시세이도 | Fibroblast proliferator |
US8628783B2 (en) | 2009-03-30 | 2014-01-14 | Shiseido Company, Ltd. | Method for growing fibroblasts |
Also Published As
Publication number | Publication date |
---|---|
JPH09295928A (en) | 1997-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3748941B2 (en) | Anti-aging cosmetic | |
CN107106480B (en) | Cosmetic composition containing fermented extract of halomonas and application thereof | |
KR100822352B1 (en) | Method for preparing a composition by mother-of-pearl extraction, comprising integrally mother-of-pearl components, composition obtained by said method and use thereof in cosmetics and dermatology | |
CN110997694A (en) | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | |
CN115581633B (en) | New use of peptide compounds in preparation of composition for skin aging repair | |
KR101869971B1 (en) | Cosmetic compositon containing natural extracts and natural mineral | |
CN109010195A (en) | A kind of whitening Wrinkle-and scar-removing repairs face cream and preparation method thereof | |
JP3302535B2 (en) | Epithelial cell growth promoter | |
KR102328010B1 (en) | A composition comprising extract of Artemisia and Engineering EGF for anti-wrinkle or moisturizing | |
KR20120020716A (en) | Cosmetic composition for improving skin elasticity | |
CN116098828A (en) | New use of tetrapeptide derivatives for preparing composition for skin repair and tightening | |
KR100361433B1 (en) | Anti-aging cosmetic compositions containing an Extract obtained from Panax ginseng | |
Xu et al. | Wound healing activity of a skin substitute from residues of culinary-medicinal winter mushroom flammulina velutipes (agaricomycetes) cultivation | |
EP2830585A2 (en) | Topical composition comprising bioactive sulfated oligosaccharides and cosmetic uses | |
CN112870102A (en) | Cosmetic composition containing glycerol glucoside and preparation method and application thereof | |
KR20160143003A (en) | The extraction procedure for iceplant's active constituent | |
CN111568781A (en) | Skin care gel and preparation method thereof | |
JP3907856B2 (en) | Cosmetics | |
CN106974880A (en) | A kind of moisturiser based on marine organism extract | |
ITFI20120104A1 (en) | SACCHARID FRACTION FROM WHEAT, PROCESS FOR ISOLATION AND USE. | |
KR101099665B1 (en) | A cosmetic composition comprising the aplysia kurodai extract for skin moisturizing effect and improving skin wrinkles | |
CN114057830B (en) | Oligopeptide-1 derivatives, preparation method and application thereof | |
CN108969397A (en) | A kind of active peptides facial mask and preparation method thereof | |
KR20060122488A (en) | Cosmetic composition for anti-wrinkle comprising the extract of chelidonium majus as active ingredient | |
KR102047442B1 (en) | Composite for mask pack |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040810 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041008 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051011 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051031 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20051129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051130 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081209 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091209 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101209 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111209 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111209 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121209 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121209 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131209 Year of fee payment: 8 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |